共 50 条
Structure-activity exploration of a small-molecule Lipid II inhibitor
被引:9
|作者:
Fletcher, Steven
[1
]
Yu, Wenbo
[1
,2
]
Huang, Jing
[1
,2
]
Kwasny, Steven M.
[3
]
Chauhan, Jay
[1
]
Opperman, Timothy J.
[3
]
MacKerell, Alexander D., Jr.
[1
,2
]
de Leeuw, Erik P. H.
[4
,5
]
机构:
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Pharm, Comp Aided Drug Design Ctr, Baltimore, MD 21201 USA
[3] Microbiotix Inc, Worcester, MA USA
[4] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
来源:
基金:
美国国家卫生研究院;
关键词:
computer-aided drug design;
Lipid II;
antibiotics;
phospholipid;
GENERAL FORCE-FIELD;
PEPTIDOGLYCAN-BIOSYNTHESIS;
STAPHYLOCOCCUS-AUREUS;
CHARMM;
ANTIBIOTICS;
MECHANISM;
BINDING;
VALIDATION;
AUTOMATION;
DEFENSINS;
D O I:
10.2147/DDDT.S79504
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
We have recently identified low-molecular weight compounds that act as inhibitors of Lipid II, an essential precursor of bacterial cell wall biosynthesis. Lipid II comprises specialized lipid (bactoprenol) linked to a hydrophilic head group consisting of a peptidoglycan subunit (N-acetyl glucosamine [GlcNAc]-N-acetyl muramic acid [MurNAc] disaccharide coupled to a short pentapeptide moiety) via a pyrophosphate. One of our lead compounds, a diphenyl-trimethyl indolene pyrylium, termed BAS00127538, interacts with the MurNAc moiety and the isoprenyl tail of Lipid II. Here, we report on the structure-activity relationship of BAS00127538 derivatives obtained by in silico analyses and de novo chemical synthesis. Our results indicate that Lipid II binding and bacterial killing are related to three features: the diphenyl moiety, the indolene moiety, and the positive charge of the pyrylium. Replacement of the pyrylium moiety with an N-methyl pyridinium, which may have importance in stability of the molecule, did not alter Lipid II binding or antibacterial potency.
引用
收藏
页码:2383 / 2394
页数:12
相关论文